AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 151 min read$NUVL

Turner Christopher Durant sold (to issuer) 55,450 shares of NUVL

Turner Christopher Durant (Chief Medical Officer) sold (to issuer) 55,450 shares of Nuvalent, Inc. (NUVL) across 2 trades on 2026-07-15.

Original reporting
SEC EDGAR · Turner Christopher Durant
Published Jul 15, 2026, 10:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
medium confidence
Mentioned
$NUVL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The disclosure updates insider ownership (0 shares after sale) but provides no new operational, financial, or regulatory information about Nuvalent.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive repricing without accompanying fundamentals.

03

What to watch

Price is not disclosed and the filing does not state the issuer’s rationale; without context (e.g., buyback program terms), interpreting directionality is unreliable.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-15, same day as the insider sale.

Background

The article is a primary-source SEC Form 4 insider transaction for Nuvalent, Inc.

Company-level read

Ticker impact

$NUVLNeutralMedium confidence
Context

Nuvalent CMO Turner Christopher Durant sold 55,450 shares to the issuer via Form 4, leaving him with 0 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 shows a same-day sale to issuer (buyback participation or similar) with price not disclosed and no 10b5-1 plan, but the filing alone does not reveal new company fundamentals.

Market effects

Sector

No sector read-across; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is coded as “to issuer,” it may reflect routine buyback participation or liquidity mechanics rather than a bearish view.

Key entities

  • issuer
    Nuvalent, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Turner Christopher Durant

    Chief Medical Officer who sold 55,450 shares to the issuer.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUVL insider trading history →

Related articles

JUL 15
$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

investegate.co.uk4 min
JUN 10
$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

finance.yahoo.com7 min
JUN 9
$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

latimes.com6 min
JUN 9
$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

benzinga.com7 min
JUN 9
$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

rttnews.com6 min
JUN 9
$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.

benzinga.com4 min